We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02765802
Recruitment Status : Completed
First Posted : May 9, 2016
Last Update Posted : March 24, 2021
Information provided by (Responsible Party):
Eiger BioPharmaceuticals

Brief Summary:

Lambda is the pegylated form of interferon lambda-1a (IFN-λ), a conjugate of recombinant human interleukin 29 (rIL-29) and a linear polyethylene glycol (PEG) chain. IFN-λ and interferon alpha (IFN-α) share the common interferon (IFN)-stimulated gene induction pathway that leads to broad-spectrum antiviral activities. Since IFN-α has demonstrated anti-hepatitis delta virus (HDV) activity in patients with chronic hepatitis delta (CHD), it is postulated that pegylated IFN-λ could also induce HDV ribonucleic acid (RNA) decline in patients with CHD. Based on IFN-λ's more limited receptor distribution and previous data from studies involving treatment with IFN-λ in patients with hepatitis B virus (HBV) or hepatitis C virus (HCV), it is postulated that Lambda treatment could be associated with fewer adverse effects than IFN-α treatment. This Phase II study is designed as randomized, open-label study of Lambda 120 or 180 μg subcutaneous (SC) injection weekly for 48 weeks in patients with chronic HDV infection, and the primary objectives of the study are as follows:

  • To evaluate the safety and tolerability of treatment with 2 dose levels of Lambda over a 48-week treatment period.
  • To evaluate the effect of treatment with 2 different doses of Lambda on HDV RNA levels.

Condition or disease Intervention/treatment Phase
Hepatitis D, Chronic Drug: Peginterferon Lambda-1A Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)
Actual Study Start Date : October 19, 2016
Actual Primary Completion Date : July 20, 2018
Actual Study Completion Date : December 12, 2018

Arm Intervention/treatment
Experimental: Lambda 180 μg
Lambda 180 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
Drug: Peginterferon Lambda-1A
Other Name: Lambda

Experimental: Lambda 120 μg
Lambda 120 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
Drug: Peginterferon Lambda-1A
Other Name: Lambda

Primary Outcome Measures :
  1. Change from baseline in HDV viral load. [ Time Frame: Week 48 (end of treatment) ]
  2. Change from baseline in HDV viral load [ Time Frame: Week 72 (end of follow-up) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic HDV infection of at least 6 months' duration documented by a positive HDV antibody (Ab) test, detectable and quantifiable HDV RNA by qPCR at study entry
  • Serum alanine aminotransferase (ALT) > upper limit of the normal range (ULN) and <10 × ULN at screening
  • Electrocardiogram (ECG) demonstrating no acute ischemia or clinically significant abnormality and a QT interval corrected for heart rate (QTcF) <450 ms for male patients and <460 ms for female patients
  • Thyroid-stimulating hormone (TSH) and/or free T4 within 0.8 to 1.2 × ULN, or adequately controlled thyroid function as assessed by the investigator.
  • Dilated retinal examination ≤1 year before screening
  • Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication

Exclusion Criteria:

General Exclusions:

  • Participation in a clinical trial with or use of any investigational agent within 30 days before screening, or treatment with interferons (IFNs) or immunomodulators within 12 months before screening
  • Previous use of Lambda. Patients who previously participated in a clinical trial of Lambda but are confirmed to have received placebo or other non-Lambda IFNs are allowed.
  • History or evidence of any intolerance or hypersensitivity to IFNs or other substances contained in the study medication.
  • Female patients who are pregnant or breastfeeding. Male patients must confirm that their female sexual partners are not pregnant.

Exclusions Based on Disease

  • Current or previous history of decompensated liver disease (Child-Pugh Class B or C)
  • Co-infected with human immunodeficiency virus (HIV) or hepatitis C virus (HCV)
  • Past history or current evidence of decompensated liver disease, defined as any of the following at screening:

    1. Bilirubin level ≥ 2.5 mg/dL unless due to Gilbert's disease
    2. Serum albumin level <3.5 g/dL
    3. International normalized ratio (INR) ≥1.5
    4. Alpha fetoprotein ≥100 ng/mL
  • Evidence of significant portal hypertension; current presence or history of variceal bleeding, ascites requiring diuretics or paracentesis, or hepatic encephalopathy
  • Any of the following abnormal laboratory test results at screening:

    1. Platelet count <90,000 cells/mm^3
    2. White blood cell count <3,000 cells/mm^3
    3. Absolute neutrophil count <1,500 cells/mm^3
    4. Hemoglobin <11 g/dL for women and <12 g/dL for men
    5. Serum creatinine concentration ≥1.5× ULN
    6. Confirmed creatinine clearance (CrCl) < 50 mL/min by Cockcroft-Gault
  • Evidence of another form of viral hepatitis or another form of liver disease
  • History of hepatocellular carcinoma
  • Patients with any of the following:

    1. Current eating disorder or alcohol abuse
    2. Excessive alcohol intake
    3. In the opinion of the investigator, an alcohol use pattern that will interfere with study conduct
    4. Drug abuse within the previous 6 months before screening, with the exception of cannabinoids and their derivatives
  • Prior history or current evidence of any of the following:

    1. Immunologically mediated disease
    2. Retinal disorder or clinically relevant ophthalmic disorder
    3. Any malignancy within 5 years before screening
    4. Cardiomyopathy or significant ischemic cardiac or cerebrovascular disease.
    5. Chronic pulmonary disease
    6. Pancreatitis
    7. Severe or uncontrolled psychiatric disorder
    8. Active seizure disorder
    9. Bone marrow or solid organ transplantation
  • Other significant medical condition that may require intervention during the study

Exclusions Based on Concurrent Medication Use

  • Therapy with an immunomodulatory agent
  • Use of telbivudine
  • Current use of heparin or Coumadin
  • Received blood products within 30 days before study randomization
  • Use of hematologic growth factors within 30 days before study randomization
  • Systemic antibiotics, antifungals, or antivirals for treatment of active infection other than HBV within 14 days before study randomization
  • Any prescription or herbal product that is not approved by the investigator
  • Long-term treatment (> 2 weeks) with agents that have a high risk for nephrotoxicity or hepatotoxicity unless it is approved by the medical monitor
  • Receipt of systemic immunosuppressive therapy within 3 months before screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02765802

Layout table for location information
Soroka Medical Center
Beersheba, Israel, 84101
Shaare Zedek Medical Center
Jerusalem, Israel, 9103102
New Zealand
Auckland City Hospital
Grafton, Auckland, New Zealand, 1142
The Aga Khan University and Hospital
Karachi, Pakistan, 74800
Sponsors and Collaborators
Eiger BioPharmaceuticals
Layout table for investigator information
Study Director: David Apelian, MD, PhD, MBA Eiger BioPharmaceuticals
Layout table for additonal information
Responsible Party: Eiger BioPharmaceuticals
ClinicalTrials.gov Identifier: NCT02765802    
Other Study ID Numbers: EIG-LMD-001
First Posted: May 9, 2016    Key Record Dates
Last Update Posted: March 24, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Virus Diseases
Hepatitis D
Hepatitis D, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepatitis, Chronic